U.S. Markets open in 5 hrs 9 mins

AgeX Therapeutics, Inc. (AGE)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
1.4900+0.0500 (+3.47%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4400
Open1.5000
Bid1.4000 x 800
Ask1.4800 x 900
Day's Range1.4500 - 1.5100
52 Week Range0.7500 - 3.9300
Volume61,524
Avg. Volume145,419
Market Cap56.523M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-0.2880
Earnings DateNov 16, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
    Business Wire

    AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update

    AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the quarter ended March 31, 2021.

  • AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update
    Business Wire

    AgeX Therapeutics Reports Fourth Quarter and Annual 2020 Financial Results and Provides Business Update

    AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, reported its financial and operating results for the fourth quarter and the full year ended December 31, 2020.

  • AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer
    Business Wire

    AgeX Announces Preprint Article Relating to Regeneration, Aging, and Cancer

    AgeX Therapeutics, Inc. ("AgeX"; NYSE American: AGE), a biotechnology company developing therapeutics for human aging and regeneration, announced today the online publication of data relating to regeneration, aging, and cancer in bioRxiv. The paper titled "Differential Expression of α, β, and γ Protocadherin Isoforms During Differentiation, Aging, and Cancer" presents for the first time data relating to mechanisms cells may use in the process of regeneration. The paper discloses alterations in certain genes that may prevent regeneration from occurring in adult humans. It also provides evidence that the family of genes may be involved in a wide array of human cancers.